Invesco
DNTH icon

Invesco’s Dianthus Therapeutics DNTH Stock Holding History

Invesco’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.34M Sell
85,603
-45,144
-35% -$3.94M ﹤0.01% 1996
2026
Q1 		$11M Buy
130,747
+29,258
+29% +$1.69M ﹤0.01% 1782
2025
Q4 		$4.18M Buy
101,489
+56,560
+126% +$2.19M ﹤0.01% 2325
2025
Q3 		$1.77M Buy
44,929
+23,989
+115% +$613K ﹤0.01% 2666
2025
Q2 		$390K Buy
20,940
+4,962
+31% +$93.1K ﹤0.01% 3273
2025
Q1 		$290K Buy
15,978
+4,457
+39% +$98.2K ﹤0.01% 3368
2024
Q4 		$251K Buy
11,521
+790
+7% +$20.3K ﹤0.01% 3467
2024
Q3 		$294K Sell
10,731
-404
-4% -$11.3K ﹤0.01% 3426
2024
Q2 		$288K Buy
+11,135
New +$268K ﹤0.01% 3520
2022
Q2 		– Sell
-708
Closed -$33K – 4066
2022
Q1 		$33K Buy
708
+14
+2% +$765 ﹤0.01% 3958
2021
Q4 		$49K Sell
694
-116
-14% -$11.7K ﹤0.01% 3983
2021
Q3 		$95K Buy
810
+125
+18% +$14.6K ﹤0.01% 3948
2021
Q2 		$107K Buy
+685
New +$126K ﹤0.01% 3882
2019
Q2 		– Sell
-3,341
Closed -$880K – 3734
2019
Q1 		$880K Buy
+3,341
New +$576K ﹤0.01% 3087

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Invesco's DNTH Position: Q2 2026 in Review

Invesco reduced its Dianthus Therapeutics (DNTH) stake by 35% in Q2 2026, selling an estimated $3.94M and leaving 85,603 shares worth $8.34M. The position accounts for ﹤0.01% of the portfolio, ranked #1996.

Invesco first reported a position in DNTH in Q1 2019 and has held it in 14 quarters since. The position peaked at $11M in Q1 2026. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Invesco held 85,603 shares of Dianthus Therapeutics worth $8.34M as of Q2 2026.
  • Invesco sold 45,144 Dianthus Therapeutics shares in Q2 2026, an estimated $3.94M.
  • Dianthus Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #1996 holding.
  • Invesco first reported a position in Dianthus Therapeutics in Q1 2019 and has held it in 14 quarters since.
  • Invesco's Dianthus Therapeutics position peaked at $11M in Q1 2026.
  • 269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.